Levosimendan in Acute Kidney Injury Study

Phase 2

Brief Summary: We hypothesise that levosimendan will have a positive influence on renal function during acute kidney injury in adult intensive care patients.

Detailed Description: The purpose of this trial is to evaluate whether the use of levosimendan is able to improve renal function.

Recruitment & Eligibility

Inclusion Criteria

Exclusion Criteria

Failure to obtain written consent to participate from patient or legal representative (by deferred consent)
Patients entering the ICU for post-operative observation with an estimated length of stay less than 24 hrs.
Moribund patients
Patients under the age of 18
Pregnancy
Patients suffering from pre-existing renal failure (elevated NGAL values without apparent rise in creatinine values)
Renal replacement therapy initiated before admission due to Chronic Kidney Disease
Hypersensitivity to levosimendan experienced by previous treatments
Severe hypotension and tachycardia
Significant mechanical obstruction affecting ventricular filling or outflow or both.
Severe hepatic impairment (ALAT/ASAT>400U/L)
Patients will be excluded if the treating physician judges that study participation is undesirable for medical, medical-ethical or other reasons
Known history of Torsades de Pointes

Arm && Interventions

Group	Intervention	Description
Conventional therapy	Conventional therapy	Standard of care as protocolized locally
Levosimendan	Levosimendan	The experimental group receives standard treatment supplemented by levosimendan (0.2 µg/kg/min) for 24 hours within 36 hrs following onset of AKI.

Primary Outcome Measures

Name	Time	Method
Change in renal function	Baseline and every 24 hours until end ICU stay	Daily analysis of kidney function expressed in endogenous creatinine clearance

Secondary Outcome Measures

Name	Time	Method

Receive instant email notifications about changes in this clinical trial

Receive instant email notifications about changes in this clinical trial